The drug discovery enzymes market is likely to be worth USD 1,751.3 million by 2033, from its projected value of USD 932.4 million in 2023. A 6.5% CAGR in the market is predicted during the forecast period. The global market experienced a CAGR of 4.2% over the preceding period between 2018 and 2022.
The overall market share is projected to rise as more sectors, including biotechnology, pharmaceuticals, food, and beverage, embrace these enzymes for various analyses. These industries are concentrating on finding additional enzymes to develop useful medications.
The demand for drug discovery enzymes to produce intermediates to manufacture active pharmaceutical ingredients (API) for effective medications is rising. However, the biofuel industry has extensively used enzymes like lipase to convert free fatty acids in recent years.
| Report Attributes or Data Points | Details |
|---|---|
| Global Drug Discovery Enzymes Market Valuation in 2022 | USD 886.6 million |
| Estimated Global Market Share in 2023 | USD 932.4 million |
| Forecasted Global Market Size by 2033 | USD 1,751.3 million |
| Projected Global Market Growth Rate from 2023 to 2033 | 6.5% CAGR |
| Historical Market Growth Rate from 2018 to 2022 | 4.2% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Factors | Explanation |
|---|---|
| Research & Development | Companies in the pharmaceutical, biopharmaceutical, and medical device industries make significant investments in the creation of novel drugs and technologies that increase the adoption of drug discovery enzymes. However, in recent years, phase III and preclinical phases have received the lion's share of their funding. An increase in R&D spending is one of the main factors influencing the worldwide market. The need for various preclinical and clinical services during the drug discovery and development process motivates the growth. |
| Target Specific Drugs | As manufacturers use enzymes to create more relevant medications that target certain action areas, the market for drug discovery enzymes is anticipated to expand throughout the forecast period. Furthermore, to identify the R-ATA enzyme from soil bacteria, Kaneka Corporation and the University of Tokyo worked together in the biotechnology and development wing. |
| Innovations | The food business is using a finite amount of enzymes to extend food's shelf life and enhance flavor. MetXtra is a newly developed food enzyme in the market. The search for and production of novel enzymes for testing samples takes less time and money, thanks to this new enzyme. During the anticipated period, these factors are likely to drive the demand for drug discovery enzymes to rise. However, in recent years, research institutions have innovated and focused on drug discovery enzymes to expand application domains. |
Handling and safety hazards connected with enzymes and increased sensitivity to temperature and pH are expected to limit market expansion. Furthermore, high financial costs and difficulties in participant recruitment and retention slow down market growth.
Additionally, deficiencies in the clinical research workforce, drug sponsor-imposed barriers, and barriers related to clinical research globalization may all harm the market growth.
Principal Consultant
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| North America | 42.7% |
| Europe | 22.2% |
Asia Pacific is expected to be the fastest-growing market during the forecast period. However, due to the introduction of novel enzymes used to treat various chronic illnesses and a rise in development strategies by leading companies, there is rising market growth in the region.
Furthermore, the region is growing rapidly due to the availability of highly skilled labor with low-cost charges and due to environmental regulations in recent years.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| United States | 38.1% |
| Germany | 4.7% |
| Japan | 5.2% |
Regarding pharmaceutical R&D investment, North America dominates the overall market during the forecast period. It is also the leading market for final dose formulations and bulk pharmaceuticals.
The market runs as a free economy, with transparent trading procedures and restrictions on anti-competitive behaviors. The region adopted high techniques with well-established infrastructure, which propelled the market growth in recent years.
The United States market is expected to become one of the primary competitors for biosimilars by 2020. Remicade, Enbrel, Rituximab, Adalimumab, Infliximab, Etanercept, Darbepoetin Alpha, and other key medications are available in the United States market. As a result of the aforementioned reasons, the market is expected to develop rapidly over the projected period.
| Regional Markets | CAGR (2023 to 2033) |
|---|---|
| United Kingdom | 4.5% |
| China | 7.8% |
| India | 6.4% |
| Australia | 5.7% |
Start-Ups Companies in the Drug Discovery Enzymes Market
To untangle the drug discovery process. Artificial intelligence and machine learning have given the pharmaceutical business new hope. AI tools enable researchers to develop innovative medications with the required features rapidly. Using these new methods, several businesses are developing innovative medicinal compounds. Some notable start-up companies are as follows:
| Category | By Product Type |
|---|---|
| Top Segment | Active Kinases |
| Market Share in Percentage | 18.5% |
| Category | By Therapeutic Ares |
|---|---|
| Top Segment | Oncology |
| Market Share in Percentage | 25.4% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Various prominent players have been researching drug discovery enzymes in recent years. Pharmaceutical scientists are developing several drug enzymes that have helped to cure patients' critical diseases in recent years.
Some recent developments in the Drug Discovery Enzymes industry are as follows:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 6.5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Product Type, End User, Region |
| Regions Covered | North America; Latin America; East Asia; South Asia; Oceania; The Middle East and Africa |
| Key Countries Profiled | United States, Canada, Brazil, Argentina, Germany, United Kingdom, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASEAN, GCC, South Africa |
| Key Companies Profiled | Sigma-Aldrich Co. LLC.; Kaneka Corporation; Actelion Pharmaceuticals Ltd; Genesis Biotechnology Group; Suven Life Sciences Limited; Enzo Life Sciences, Inc.; Merck KGaA |
| Customization | Available Upon Request |
The projected market value by the end of 2033 is USD 1,751.3 million.
The market was valued at nearly USD 886.6 million in 2022.
Handling and safety hazards connected with enzymes and increased sensitivity to temperature and pH are expected to limit market expansion.
North America holds a market share of 42.7% in the global market.
Active Kinases account for a share of 18.5% in the global market.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type 5.1. Active Kinases 5.2. Ubiquitin 5.3. Epigenetic 5.4. Methyltransferases 5.5. Deacetylases 5.6. Phosphodiesterases 5.7. Others 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 6.1. Pharmaceutical and Biotechnology Company 6.2. Research Institutes 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Western Europe 7.4. Eastern Europe 7.5. South Asia and Pacific 7.6. East Asia 7.7. Middle East and Africa 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Sigma-Aldrich Co. LLC. 17.2. Kaneka Corporation 17.3. Actelion Pharmaceuticals Ltd 17.4. Genesis Biotechnology Group 17.5. Suven Life Sciences Limited 17.6. Enzo Life Sciences, Inc. 17.7. Merck KGaA 17.8. Pfizer Inc 17.9. Agilent Technologies Inc 17.10. Eli Lilly and Company 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Drug Discovery Enzymes Market
